1 Major Articles

2	Influenza vaccine effectiveness against hospital-attended
3	influenza infection in 2023/24 season in Hangzhou, China
4	
5	Hao Lei <sup>1#</sup> , Beidi Niu <sup>1#</sup> , Zhou Sun <sup>2</sup> , Yaojing Wang <sup>3</sup> , Xinren Che <sup>2</sup> ,
6	Shengqiang Du <sup>1,4</sup> , Yan Liu <sup>2</sup> , Ke Zhang <sup>5</sup> , Shi Zhao <sup>6,7,8</sup> , Shigui Yang <sup>1</sup> , Zhe
7	Wang <sup>2*</sup> , Gang Zhao <sup>2*</sup>
8	
9	<sup>1</sup> School of Public Health, Zhejiang University School of Medicine,
10	Hangzhou, P.R. China
11	<sup>2</sup> Hangzhou Disease Prevention and Control Center, Hangzhou, P.R.
12	China
13	<sup>3</sup> School of Economics, Peking University, Beijing, P.R. China
14	<sup>4</sup> Wuxing Center for Disease Control and Prevention, Huzhou, P.R. China
15	<sup>5</sup> Hangzhou First People's Hospital, Hangzhou, P.R. China
16	<sup>6</sup> School of Public Health, Tianjin Medical University, Tianjin, China
17	<sup>7</sup> Tianjin Key Laboratory of Environment, Nutrition and Public Health,
18	Tianjin Medical University, Tianjin, China
19	<sup>8</sup> MoE Key Laboratory of Prevention and Control of Major Diseases in the
20	Population, Tianjin Medical University, Tianjin, China
21	<sup>#</sup> Contributed equally

22 \*Corresponding author

23

#### 24 Abstract

25 Background: From 2020, influenza activities were largely affected by
26 the coronavirus disease (COVID-19) pandemic at the global scale. The
27 B/Yamagata lineage has become extinct since 2020, raising concerns
28 regarding the quadrivalent influenza vaccine. Evaluating vaccine
29 effectiveness (VE) against influenza infections is important to guide
30 future influenza vaccine programs.

Methods: A test-negative case-control study was conducted in five
tertiary hospitals in Hangzhou, the capital city of Zhejiang province,
China. Hospital-attended patients aged >6 months who presented with
influenza-like illness (ILI) from October 1, 2023 to March 31, 2024 were
enrolled in this study. The VE was estimated using multivariate logistic
regression models, adjusted by sex, age, influenza detection methods and
influenza testing timing.

38 Results: In total, 157291 hospital-attended ILI participants were enrolled.
39 56704 (36%) were tested positive for influenza virus. The adjusted
40 estimates of overall VE against any hospital-attended influenza infection
41 was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of
42 trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI:
43 50%-66%), followed by trivalent live attenuated vaccine (LAIV3)
44 (VE=53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza

45	vaccine (IIV4) (VE=47%, 95% CI: 45%-50%). IIV3 provided even much									
46	better protection against hospital-attended influenza B infection than IIV4									
47	(VE=87% (95% CI: 81%-92%) for IIV3 versus VE=53%, 95% CI:									
48	50%-57% for IIV4).									
49	Conclusions: The influenza vaccine provided moderate protection									
50	against influenza infection in the 2023/24 season in Hangzhou, China,									
51	during a massive epidemic. The results supported the World Health									
52	Organization recommendation regarding the exclusion of B/Yamagata									
53	lineage antigen in quadrivalent influenza vaccines in 2023.									
54	Keywords: Vaccine effectiveness; seasonal influenza; test-negative study;									
55	influenza B; IIV3.									

57

### 58 Introduction

59 Influenza vaccination is the most effective way to prevent influenza **60** infection [1]; however, the influenza vaccine effectiveness (VE) can vary 61 considerably from year to year [2]. From 2020, the COVID-19 pandemic 62 greatly disturbed influenza activities [3, 4]. In the 2023/24 season, a sharp 63 increase in influenza activities was observed in China [5]. In addition, the 64 B/Yamagata lineage became extinct in 2020, raising concerns regarding 65 the quadrivalent influenza vaccine situation [6]. In September 2023, the 66 World Health Organization (WHO) proposed that the inclusion of a B/ 67 Yamagata lineage antigen in quadrivalent influenza vaccines is no longer 68 warranted, and every effort should be made to exclude this component as **69** soon as possible. [7]. Thus, evaluation of effectiveness of trivalent and 70 quadrivalent influenza vaccines, especially the quadrivalent influenza 71 vaccine, in the years without the B/Yamagata lineage has become 72 significant. Globally, several studies have evaluated early or interim 73 influenza VE after the COVID-19 pandemic [8-11]. However, to the best 74 of our knowledge, no study had estimated the influenza VE for the entire 75 flu season in 2023/24. As the timing of influenza vaccination plays a role 76 in estimating its effectiveness [12], the influenza VE during the entire flu 77 season may differ from the early or interim VE. To the best of our 78 knowledge, no study has compared VE between trivalent and

79 quadrivalent influenza vaccines in the 2023/24 season.

80

81 Since 2020, Zhejiang Province has provided free influenza vaccines to 82 older adults aged >70 years [13]. This program provided an opportunity 83 to evaluate the effectiveness of influenza vaccination policies in the real 84 world. Recently, three types of influenza vaccines have been used in 85 China: trivalent inactivated influenza vaccine (IIV3), quadrivalent 86 inactivated influenza vaccine (IIV4), and trivalent live attenuated vaccine 87 (LAIV3) [14]. For the trivalent influenza vaccine, in the 2023-2024 **88** season, B/Victoria was used [15], and LAIV3 was used only in children 89 aged 3-14 years.

90

91 Isolation of the virus and testing using real-time reverse-transcription 92 polymerase chain reaction (RT-PCR) is adopted as the gold standard 93 reference method for the diagnosis of the influenza [16]. And a 94 test-negative case-control study design has been widely used to evaluate 95 influenza VE [17]. However, small sample sizes and large ranges of the 96 95% confidence intervals (CIs) of the estimated VE have limited the 97 robustness of the results, especially in China, with a relatively low 98 influenza vaccination rate, which was approximately 1.5%-2.2% before 99 the COVID-19 pandemic [18] and slight increased after the pandemic to 100 3.16% in 2020/21 season and 2.47% in 2021/22 season [19]. Although

101 their sensitivity is relatively low, commercially available rapid antigen 102 detection tests have the advantage of providing results much more 103 quickly [16] and have been more widely used in hospitals in China. Thus, 104 the large number of influenza-like illness (ILI) cases identified by antigen 105 detection provided the possibility of conducting a robust VE evaluation 106 and separate analysis of VE in subgroups in more detail. In addition, to 107 the best of our knowledge, the impact of these two influenza detection 108 methods on VE remains unknown.

109

In this study, we performed a test-negative case-control study to estimate the effectiveness of three different types of influenza vaccines against influenza infection in the 2023/24 season in Hangzhou city, China, during a period of massive influenza epidemic. We aimed to compare VE between three types of influenza vaccines (IIV3, IIV4, and LAIV3), and different age groups.

116

117 Methods

**118** Study population

119 Samples were collected from five tertiary hospitals: First People's
120 Hospital of Hangzhou, Second People's Hospital of Hangzhou, First
121 People's Hospital of Linping District, Zhejiang Xiaoshan Hospital, and
122 First People's Hospital of Xiaoshan District. Data were collected from

123 October 1, 2023, to March 31, 2024, based on the seasonality of influenza 124 epidemics in Zhejiang Province [20]. Regarding influenza detection, 125 physicians were required to specify on the laboratory requisition form 126 that the patient exhibited symptoms consistent with ILI. However, there is 127 currently no standardized case definition of ILI [8]. Each month, 128 individuals seeking medical attention for respiratory diseases with fever, 129 accompanied by symptoms of cough and sore throat, and undergoing 130 influenza testing, were enrolled in the study across the five healthcare 131 institutions.

132

133 Eligible participants were patients with ILI who visited these five sentinel 134 hospitals and were older than 6 months. Patients with an influenza testing 135 interval exceeding 14 days were eligible for repeated inclusion in the 136 study [2]. Basic demographic information, including sex and age, was 137 collected for each patient with influenza testing, along with the detailed 138 testing date, type of test method, and corresponding test results. Influenza 139 testing methods included influenza nucleic acid detection by RT-PCR and 140 influenza antigen detection. These two detection methods were analyzed 141 individually to test the effect of the detection methods on the evaluation 142 of VE. This study was approved by the Institutional Review Board and 143 Human Research Ethics Committee of the School of Medicine of 144 Zhejiang University (No. ZGL202404-1).

145

### **146** Vaccination status

147 The virus strains recommended by the WHO in in the 2024 Northern 148 Hemisphere influenza season were A/Victoria/4897/2022 (H1N1) 149 pdm09-like virus. A/Darwin/9/2021 (H3N2)-like virus. and 150 B/Austria/1359417/2021 (B/Victoria lineage)-like virus [15]. Patient 151 vaccination information was obtained from the Zhejiang Province 152 Electronic Medical System using the patient's identity card (ID). This 153 system comprehensively covers vaccination records for the majority of 154 Hangzhou residents, as it was constructed to record COVID-19 155 vaccination status. Patients without vaccination records were excluded. 156 Patient vaccination information from the Zhejiang Province Electronic 157 Medical System included patient ID, vaccine type (IIV3, IIV4, or LAIV3), 158 and vaccine date. This study specifically focused on the details of vaccine 159 administration for 2022 and 2023. In accordance with Zhejiang 160 Province's vaccination policy, vaccination in the current season was 161 defined as influenza vaccination from July 1, 2023, to March 31, 2024. 162 Vaccination in the previous season was defined as influenza vaccination from July 1, 2022, to June 30, 2023. To explore the impact of previous 163 164 vaccines on VE, the vaccination status of participants was categorized 165 into four types: never vaccinated, vaccinated in both seasons, vaccinated 166 only in the previous season, and vaccinated only in the current season.

Individuals were considered immunized if they had received an influenza
vaccine for at least 14 days before the specimen collection date [2].
Thus, influenza vaccines administered within 14 days before ILI onset
were excluded from the analysis. The flu vaccine produced by
manufacturers for children under 14 years of age requires two doses to be
considered a complete vaccination.

173

**174** Statistical analysis

175 We pooled 6 months of data and compared characteristics of cases 176 confirmed through influenza nucleic acid testing and influenza antigen 177 testing with the characteristics of control cases that tested negative for 178 influenza, stratified by virus type, vaccine type, and age group of patients. 179 VE was calculated using a test-negative case-control design as  $(1 - OR) \times$ 180 100, where OR is the odds ratio, which represents the odds of influenza 181 virus infection among confirmed cases (positive test results) who 182 received vaccination divided by the odds of vaccination among all 183 influenza-negative cases (negative test controls). Adjusted ORs were 184 determined using multivariate logistic regression models with 185 adjustments for sex, age, influenza detection methods and month of 186 influenza testing. Stratified VE estimates were computed based on the 187 age group and influenza virus type. All statistical tests were conducted 188 using a two-sided approach, and significance was defined as P < 0.05 or

189	when the lower bound of the 95% CI for VE was greater than 0.
190	Statistical analyses were performed using $\mathbf{R}$ statistical programming
191	software version 4.2.1 (The R Project for Statistical Computing, Vienna,
192	Austria).
193	
194	Sensitivity analysis
195	We conducted sensitivity analysis to assess the robustness of the
196	estimated influenza VE. Firstly, we estimated the influenza VEs based on
<b>197</b>	two influenza detection methods individually to test the impact of
198	influenza detection methods. Second, to test the impact of influenza
199	testing timing, we did not adjust the influenza testing timing or adjust the
200	influenza testing data to estimate the VE individually.
200 201	influenza testing data to estimate the VE individually.
	influenza testing data to estimate the VE individually. Results
201	
201 202	Results
201 202 203	Results Participant characteristics
<ul><li>201</li><li>202</li><li>203</li><li>204</li></ul>	Results Participant characteristics Data were collected from October 1, 2023, to March 31, 2024, involving
<ul> <li>201</li> <li>202</li> <li>203</li> <li>204</li> <li>205</li> </ul>	Results Participant characteristics Data were collected from October 1, 2023, to March 31, 2024, involving a total of 157291 ILI patients tested for influenza (Table 1). Of which,
<ul> <li>201</li> <li>202</li> <li>203</li> <li>204</li> <li>205</li> <li>206</li> </ul>	Results Participant characteristics Data were collected from October 1, 2023, to March 31, 2024, involving a total of 157291 ILI patients tested for influenza (Table 1). Of which, 151,251 were tested by antigen and 6,040 were tested by nucleic acid
<ul> <li>201</li> <li>202</li> <li>203</li> <li>204</li> <li>205</li> <li>206</li> <li>207</li> </ul>	Results Participant characteristics Data were collected from October 1, 2023, to March 31, 2024, involving a total of 157291 ILI patients tested for influenza (Table 1). Of which, 151,251 were tested by antigen and 6,040 were tested by nucleic acid (Table S1). The number of ILI patients tested for influenza peaked at

211 patients during the study period (Table 1), and the influenza positivity 212 rates peaked at week 52 in 2023 at 49.9% (5,798/11,629) (Figure 1). By 213 the end of this study, March 31, 2024, influenza activities also almost 214 ended in Hangzhou (Figure 1). The weekly influenza positive rates of two 215 detection methods were highly related (Pearson r=0.94, P < 0.001) 216 (Figure S1). In the ILI patients, female was a little more than male 217 (53.6% versus 46.4%). And people with the age between 18-59 years 218 accounted for the highest proportion, comprising 50.4%. The overall 219 influenza vaccine coverage rate was 7.1% (Table 1), with a coverage rate 220 of 4.5% for positive cases and 8.6% for negative cases. The influenza 221 vaccine coverage rate in the nucleic acid-tested patients was higher than 222 that in the antigen-tested ILI patients (13.7% VS 6.8%) (Table S1), the 223 main reason could be the much higher percentage of 70+ old people in 224 the acid-tested participates than that in the antigen-tested patients (19.8%) 225 VS 1.14%), and higher vaccine coverage rate in old people (44.8% VS 226 21.7%) (Table S2). For these people who vaccinated in the 2023/24227 season, the majority opted for IIV4, accounting for 86.3%, followed by 228 IIV3 (8.8%) and LAIV3 (4.9%). And for these who vaccinated IIV3, 229 most of them were older people with age more 70 years because the IIV3 230 influenza vaccines administered to older adults were free (Table S3). For 231 people who were vaccinated in 2023-2024, the period between the 232 influenza test date and the influenza vaccination date ranged from 15 to

**233** 249 days with a median of 97 days (Figure S2).

234 Overall VE

235 After adjustment for potential confounders, the estimated overall 236 influenza VE against hospital-attended influenza infection in the 2023/24237 season was 48% (95% confidence interval (CI): 46%-51%) (Figure 2). 238 VE estimates were consistent between subjects using two influenza virus 239 testing methods: 48% (95% CI: 46%-51%) for antigen-tested subjects, 240 and 55% (95% CI: 44%-63%) for nucleic acid-tested subjects (Figure S3). 241 However, because of the much larger number of patients detected by 242 antigen testing, the estimated 95% CI of VE was much narrower. In 243 addition, without adjusting the influenza testing timing or adjusted by the 244 influenza testing date also had very limited impact on estimating the 245 overall VEs (Figure S4). The overall VE of IIV3 was highest (VE=59%, 246 95% CI: 50%-66%), followed by LAIV3 (VE=53%, 95% CI: 42%-62%) 247 and IIV4 (VE=47%, 95% CI: 45%-50%) (Figure 2). Adjusted VE was 248 65% for children aged 6 months to 2 years, 52% for people aged 18-59 249 years, 78% for old adults aged 60-69 years, and 28% for people aged 250 above 70 (Figure 2). The VE against hospital-attended influenza B 251 infection (VE=57%, 95% CI: 54%-60%) was much higher than that 252 against influenza A infection (VE=38%, 95% CI: 34%-42%). (Figure 2). 253

254

255 VE by influenza subtype, vaccine type and age group

256	Overall,	influenza	vaccine	provided	better	protection	against					
257	hospital-attended influenza B infection than against influenza A infection											
258	in 2023/24 season in Hangzhou. IIV3 provided much better protection											
259	than IIV4 against hospital-attended influenza B infection (Figure 3). The											
260	adjusted V	VE of IIV3	against in	nfluenza B	infection	was 87% (9	95% CI:					
261	81%-92%	), much hig	her than tl	hat of IIV4	against i	influenza B i	nfection					
262	(VE=53%	, 95% CI: 5	0%-57%).	LAIV3 also	o provide	ed high prote	ction for					
263	children a	ged 3-17 ye	ars against	: influenza E	infectio	n (VE=79%,	95% CI:					
264	69%-86%	) (Figure 3)	. Though	adjusted by	age and	testing timi	ng, IIV4					
265	provided	best protecti	on against	t hospital-at	tended in	nfluenza A in	nfection,					
266	followed by LAIV3 and IIV3.											

267

268

**269** VE for different vaccination seasons

VE against hospital-attended influenza infection was the highest for those
vaccinated only in the current 2023/24 season (VE=52%, 95%
CI=49%-55%) (Figure 4). Vaccination in the previous 2022/23 season
could only provide low protection against hospital-attended influenza
infection (VE=23%, 95% CI=18%-27%). However, vaccination in the
previous 2022/23 season could still provide moderate protection against
hospital-attended influenza B infection (VE=34%, 95% CI: 28%-40%).

277	And vaccination in both seasons provided best protection against
278	influenza B infection (VE=59%, 95% CI: 55%-63%). However, for
279	influenza A, vaccination in the current season only provided best
280	protection (VE=47%, 95% CI: 52%-60%) (Figure 4).

- 281
- 282
- 283 Discussion

284 Several studies have evaluated the effectiveness of influenza vaccines 285 after the COVID-19 pandemic. In Denmark, VE was low at 24.8% in 286 non-hospitalized patients aged 7-44 years in the 2021/22 season when 287 there was a sharp increase in influenza detections [9]. In China, in the 288 2022/23 season when there was a slight increase in influenza infections, 289 the estimated influenza VE was 56.3% against influenza infection in 290 medically attended [10]. Several studies have estimated the effectiveness 291 of early or interim influenza vaccines in the 2023-2024 season. In Canada, 292 the estimated early influenza VE was 61% against influenza A H1N1, 293 49% against influenza A H3N2, and 75% against influenza B in the 294 2023/24 season [8]. In the Southern Hemisphere, the estimated interim 295 influenza VE was 51.9% against influenza hospitalization in the 2023/24 296 flu season [11]. In California in the United States, the estimated interim 297 influenza vaccine effectiveness against laboratory-confirmed influenza

**298** was 45% among persons aged  $\ge 6$  months [21]. However, to the best of

299 our knowledge, no study has estimated the VE for the entire 2023/24 300 season. As the timing of influenza vaccination plays a role its 301 effectiveness [12], the VE in the entire flu season may differ from the 302 early or interim VE and would be more accurate in estimating the 303 cost-effectiveness of the free influenza vaccination program. In this study, 304 the estimated VE against influenza infection was 48% in the 2023/24 305 season in Hangzhou, China, which was close to the estimated interim VE 306 in the Southern Hemisphere and US in the 2023/24 season [11, 21], And 307 the estimated overall VE was robust to the influenza detection methods 308 and influenza testing timing. The estimated VE in this study was much 309 lower than the estimated early influenza VE in Canada [8], the timing of 310 the studies may play a key role. However, similar to the study results in 311 Canada, our study also found that influenza vaccines provided better 312 protection against influenza B than influenza A in the 2023/24 season.

313

Before the COVID-19 pandemic, several studies also had evaluated the
influenza VE in China in all age group in the year from 2013 to 2017
[23-25]. The estimated VE ranged from 5% (95% CI: -53%-41%) to 47%
(95% CI: -20%-77%) in these studies. The observed variations could be
due to the relatively small number of ILI patients enrolled in the studies,
since the vaccine-effectiveness point estimates always have very wide
confidence intervals in these studies. In addition, the influenza positivity

321 rates in the ILI cases in these three studies ranged from 20% to 27%
322 [23-25], much lower than the 36% influenza positivity rate in this study.
323 This may suggest a relative higher VE during massive influenza
324 epidemics, since the overall influenza VE was only 36% from a
325 meta-analysis of the influenza VE before the pandemic in China [26].

326

327 The influenza vaccine coverage was 7.1% in the ILI patients in 2023/24328 season in Hangzhou, which was much higher than the average influenza 329 vaccine coverage rate in China, i.e., 2.47% in 2021/22 season [19], but 330 was much lower than that in the United States [27]. The increased 331 influenza vaccine coverage rate mainly contributed by the increased 332 influenza vaccine coverage rate in the old people aged more than 70 years, 333 which was 28%, much higher than these in other age groups. However, in 334 Hangzhou in the 2023/24 season, we found that the majority opted IIV4, 335 accounting for 86.3%, only 8.8% of ILI cases vaccinated IIV3. And for 336 these who vaccinated IIV3, most of them were older people with age 337 more 70 years because of the free influenza IIV3 program to them (Table 338 S3). In this study, we found IIV3 provided better protection than IIV4 339 against influenza infection, especially against influenza B infection in the 340 2023/24 season (87% versus 52%). The main reason could be that 341 B/Victoria used influenza vaccine components in trivalent influenza 342 vaccine, since B/Yamagata lineage has become extinct [6]. Our results

343	supported the report from WHO about the exclusion of B/Yamagata										
344	lineage antigen in quadrivalent influenza vaccines as soon as possible [7].										
345	On March 14, 2024, the Centers for Diseases Control and Prevention of										
346	the United States. also announced the transition from quadrivalent to										
347	trivalent flu vaccines for the 2024-2025 season [22]. Since IIV3 is much										
348	cheaper than IIV4, but could provide better protection, the										
349	cost-effectiveness of IIV3 could also be much higher than IIV4.										

350

351 The findings of this study have the following limitations. First, there was 352 a preference among the population for antigen tests over nucleic acid tests, 353 resulting in a smaller patient sample size for the latter. This has led to an 354 inability to produce highly statistically reliable VE estimates in multiple 355 subgroup analyses. Consequently, VE estimates for patients diagnosed 356 using nucleic acid tests should be interpreted with caution. Second, we 357 did not acquire data on the genetic or antigenic characteristics of the 358 circulating A(H1N1) pdm09 or A(H3N2) strains in Hangzhou. Future 359 research should focus on the antigenicity and genetic characteristics of 360 these viruses to conduct more in-depth studies. Third, there are 361 limitations associated with the use of routine health data collected by 362 hospitals. For instance, the absence of symptomatic status data precludes 363 the determination of whether cases are ILIs. Additionally, because of the 364 reliance on specimen collection dates as proxies for symptom onset dates,

365	the actual date of illness onset for most individuals was likely earlier.
366	This may result in the misclassification of individuals as either
367	influenza-negative or positive. For example, if the vaccination date and
368	the onset of symptoms are close, but there is a long interval before testing.
369	Lastly, other patient information that may influence the effectiveness of
370	influenza vaccines, was not available, such as chronic diseases related to
371	severe influenza. These chronic diseases include cardiovascular diseases,
372	chronic respiratory diseases, neurological disorders, and diabetes [2].

373

374 Conclusion

375 The influenza vaccine provided moderate protection against influenza 376 infection during the massive epidemic in Hangzhou in the 2023/24 season. 377 The large number of patients with an ILI detected by antigen testing made 378 it possible to conduct a detailed separate analysis of influenza VE, such 379 as by vaccine type, age group of patients, and influenza subtype. IIV3 380 provided better protection against hospital-attended influenza infection, 381 especially influenza B. Thus, our study results support the WHO 382 recommendation regarding the exclusion of B/Yamagata lineage antigens 383 in quadrivalent influenza vaccines in September 2023.

384

### **385** Acknowledgments

**386** HL and BN conceived and designed the study. ZS, ZW, KZ, XC and YL

387	collected data. HL and BN wrote the drafts of the manuscript. BN cleaned									
388	and analyzed the data. GZ, ZW and HL supervised the study. YW, SZ									
389	and SY commented on and revised drafts of the manuscript. HL									
390	interpreted the findings. All authors read and approved the final report.									
391										
392	Funding									
393	This study was supported by the innovation group on intelligent response									
394	to infectious diseases and public health emergencies of School of Public									
395	Health, Zhejiang University.									
396										
397	Competing interests									
200										
398	All authors declare no competing interests.									
398 399	All authors declare no competing interests.									
	All authors declare no competing interests. Data Availability									
399										
399 400 401	Data Availability									
399 400 401 402	<b>Data Availability</b> The data that support the findings of this study are available from the									
399 400 401	<b>Data Availability</b> The data that support the findings of this study are available from the									
<ul> <li>399</li> <li>400</li> <li>401</li> <li>402</li> <li>403</li> <li>404</li> </ul>	Data Availability The data that support the findings of this study are available from the corresponding author upon reasonable request.									
<ul> <li>399</li> <li>400</li> <li>401</li> <li>402</li> <li>403</li> <li>404</li> </ul>	Data Availability The data that support the findings of this study are available from the corresponding author upon reasonable request. References									
<ul> <li>399</li> <li>400</li> <li>401</li> <li>402</li> <li>403</li> <li>404</li> <li>405</li> </ul>	Data Availability         The data that support the findings of this study are available from the corresponding author upon reasonable request.         References         1. Paules C, Subbarao K. Influenza. Lancet, 2017 ;									

409		England Journal of Medicine, 2017 ; 377(6): 534-543.
410	3.	Lei H, Xu M, Wang X, et al. Nonpharmaceutical interventions used to
411		control COVID-19 reduced seasonal influenza transmission in China.
412		The Journal of infectious diseases, 2020 ; 222(11): 1780-1783.
413	4.	Lei H, Yang L, Yang M, et al. Quantifying the rebound of influenza
414		epidemics after the adjustment of zero-COVID policy in China.
415		PNAS nexus, 2023; 2(5): pgad152.
416	5.	Chinese National Influenza Center. Influenza Weekly Report. Week 3,
417		2024. Available at:
418		https://ivdc.chinacdc.cn/cnic/en/Surveillance/WeeklyReport/2024
419		01/t20240125_272252.htm. Accessed 31 January 2024.
420	6.	Monto A S, Zambon M, Weir J P. The End of B/Yamagata Influenza
421		Transmission-Transitioning from Quadrivalent Vaccines. The New
422		England journal of medicine, 2024 ; 390(14):1256-1258.
423	7.	WHO. Recommended composition of influenza virus vaccines for use
424		in the 2024 southern hemisphere influenza season. Wkly Epidemiol
425		Rec 2023; 98: 521-33. Available at:
426		https://iris .who.int/bitstream/handle/10665/373645/WER9843enfre.p
427		df. Accessed 31 January 2024.
428	8.	Smolarchuk C, Ickert C, Zelyas N, et al. Early influenza vaccine
429		effectiveness estimates using routinely collected data, Alberta,
430		Canada, 2023/24 season [J]. Euro Surveill, 2024 ; 29(2).

431	9. Emborg HD, Vestergaard L S, Botnen A B, et al. A late sharp
432	increase in influenza detections and low interim vaccine effectiveness
433	against the circulating A (H3N2) strain, Denmark, 2021/22 influenza
434	season up to 25 March 2022[J]. Eurosurveillance, 2022 ; 27(15):
435	2200278.
436	10. Su Y, Guo Z, Gu X, et al. Influenza vaccine effectiveness against
437	influenza A during the delayed 2022/23 epidemic in Shihezi, China[J].
438	Vaccine, 2023 ; 41(39): 5683-5686.
439	11. Fowlkes A L. Interim Effectiveness Estimates of 2023 Southern
440	Hemisphere Influenza Vaccines in Preventing Influenza-Associated
441	Hospitalizations—REVELAC-i Network, March-July 2023[J].
442	MMWR. Morbidity and Mortality Weekly Report, 2023; 72.
443	12. Worsham C M, Bray C F, Jena A B. Optimal timing of influenza
444	vaccination in young children: population based cohort stud. BMJ,
445	2024 ; 384.
446	13. Zhang X, Shen P, Liu J, et al. Evaluating the effectiveness and
447	cost-effectiveness of free influenza vaccination policy for older adults
448	in Yinzhou, China: Study protocol of a real-world analyses. Vaccine,
449	2023 ; 41(34): 5045-5052.

450 14. TWGIV, National Immunization Advisory Committee, Technical
451 Working Group. Technical guidelines for seasonal influenza
452 vaccination in China (2023-2024). Zhonghua liu xing bing xue za zhi,

**453** 2023 ; 44(10): 1507-1530.

454	15. World Health Organization. Recommended composition of influenza
455	virus vaccines for use in the 2024 northern hemisphere influenza
456	season. 2023. Available at:
457	https://www.who.int/publications/m/item/recommended-composit
458	ion-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern
459	-hemisphere-influenza-season. Accessed 31 January 2024.
460	16. Ghebremedhin B, Engelmann I, König W, et al. Comparison of the
461	performance of the rapid antigen detection actim Influenza A&B test
462	and RT-PCR in different respiratory specimens. Journal of medical
463	microbiology, 2009 ; 58(3): 365-370.
464	17. Fukushima W, Hirota Y. Basic principles of test-negative design in
465	evaluating influenza vaccine effectiveness. Vaccine. 2017 ;
466	35(36):4796-4800.
467	18. Yang J, Atkins KE, Feng L, et al. Seasonal influenza vaccination in
468	China: Landscape of diverse regional reimbursement policy, and
469	budget impact analysis. Vaccine. 2016 ; 34(47):5724-5735.
470	19. Zhao H, Peng Z, Ni Z, et al. Investigation on influenza vaccination
471	policy and vaccination situation during the influenzaseasons of
472	2020-2021 and 2021-2022 in China. Chinese Journal of Preventive
473	Medicine, 2022 ; 56(11): 1560-1564.

474 20. Lei H, Yang L, Wang G, et al. Transmission patterns of seasonal


475	influenza	in	China	between	2010	and	2018.	Viruses,	2022	;	14(9):
476	2063.										


- 477 21. Zhu S. Interim Influenza Vaccine Effectiveness Against 478 Laboratory-Confirmed Influenza—California, October 2023–January 479 2024[J]. MMWR. Morbidity and Mortality Weekly Report, 2024; 73. 480 22. Centers for Diseases Control and Prevention. Seasonal Flu Vaccines. 481 Available at https://www.cdc.gov/flu/prevent/flushot.htm. Accessed 482 26 April 2024.
- 483 23. Qin Y, Zhang Y, Wu P, et al. Influenza vaccine effectiveness in
  484 preventing hospitalization among Beijing residents in China,
  485 2013–15[J]. Vaccine, 2016 ; 34(20): 2329-2333.
- 486 24. Zhang L, Pan Y, Hackert V, et al. The 2015–2016 influenza epidemic
- 487 in Beijing, China: Unlike elsewhere, circulation of influenza A
  488 (H3N2) with moderate vaccine effectiveness[J]. Vaccine, 2018 ;
  489 36(33): 4993-5001.
- 490 25. Wu S, Pan Y, Zhang X, et al. Influenza vaccine effectiveness in
- **491** preventing laboratory-confirmed influenza in outpatient settings: a
- **492** test-negative case-control study in Beijing, China, 2016/17 season[J].
- **493** Vaccine, 2018 ; 36(38): 5774-5780.
- 494 26. Yang X, Zhao H, Li Z, et al. Influenza vaccine effectiveness in
  495 mainland China: a systematic review and meta-analysis[J]. Vaccines,
  496 2021 ; 9(2): 79.

- 497 27. Centers for Diseases Control and Prevention. Flu Vaccination
- 498 Coverage, United States, 2022–23 Influenza Season. Available at
- 499 https://www.cdc.gov/flu/fluvaxview/coverage-2223estimates.htm
- **500** Accessed 28 April 2024.
- 501
- 502



### 504





### 508

509 Table 1. Demographic and clinical characteristics of participants who

510	tested positive or negative for influenza virus

	Test-positive participants			Test-negative	Total		
Characteristics	Influenza A	Influenza B	A/B	participants			
	Influenza A Influenza B		coinfection				
Total, n (%)	32611	24030	63	100587	157291		
Sex, n (%)							
Male	15386	11624	20(46.00)	45930	72969		
Male	(47.2%)	(48.4%)	29 (46.0%)	(45.7%)	(46.4%)		
Female	17225	12406	34 (54.0%)	54657	84322		

	(52.8%) (51.6%)		(54.3%)	(53.6%)			
Age group, n (%)							
0.5-2 years	1016 (3.1%)	679 (2.8%)	1 (1.6%)	4963 (4.9%)	6659 (4.2%)		
	7138	6190	22(26.50/)	22057	35408		
3-9 years	(21.9%)	(25.8%)	23 (36.5%)	(21.9%)	(22.5%)		
	5718	4459	0(14.20)	18532	28718		
10-17 years	(17.5%)	(18.6%)	9 (14.3%)	(18.4%)	(18.3%)		
	17681	12228	25 (20, 70/)	49336	79270		
18-59 years	(54.2%)	(50.9%)	25 (39.7%)	(49.0%)	(50.4%)		
60-69 years	680 (2.1%)	370 (1.5%)	1 (1.6%)	3352 (3.3%)	4403 (2.8%)		
70+ years	378 (1.2%)	104 (0.4%)	4 (6.3%)	2347 (2.3%)	2833 (1.8%)		
Vaccinated in 20	)23/34 season, n	u (%)					
NI-	31138	22965	5((99.00/)	91984	146143		
No	(95.5%)	(95.6%)	56 (88.9%)	(91.4%)	(92.9%)		
Yes	1473 (4.5%)	1065 (4.4%)	7 (11.1%)	8603 (8.6%)	11148 (7.1%)		
Types of Vaccin	es, n (%)						
IIV3	96 (6.5%)	19 (1.8%)	1 (14.3%)	866 (10.1%)	982 (8.8%)		
115.7.4	1278	1020	5 (71 40/)	7320	0(22 (9( 20/)		
IIV4	(86.8%)	(95.8%)	5 (71.4%)	(85.1%)	9623 (86.3%)		
LAIV3	99 (6.7%)	26 (2.4%)	1 (14.3%)	417 (4.8%)	543 (4.9%)		

	No.of Case Patients/		
Subgroup	Total No.(%)		VE (95% CI)
Overall	56704/157291(36.05)	•	0.48 (0.46-0.51)
Vaccine type			
IIV3	116/982(11.81)		0.59 (0.50-0.66)
IIV4	2303/9623(23.93)	•	0.47 (0.45-0.50)
LAIV3 (3 to 17 yr of age only)	126/543(23.20)		0.53 (0.42-0.62
Age group			
0.5-2 years	1696/6659(25.47)	-	0.65 (0.54-0.72
3-9 years	13351/35408(37.71)	•	0.43 (0.39-0.47
10-17 years	10186/28718(35.47)	+	0.42 (0.36-0.48
18-59 years	29934/79270(37.76)	-	0.52 (0.43-0.58
60-69 years	1051/4403(23.87)		0.75 (0.59-0.85
70+ years	486/2833(17.15)		0.28 (0.07-0.44
Influenza subtype			
Influenza A	32674/133261(24.52)	+	0.38 (0.34-0.42
Influenza B	24093/124680(19.32)	•	0.57 (0.54-0.60
	-0.5	0 0.5 1	_
	Vacci	ne effectiveness	

512 Figure 2. Adjusted estimates of influenza vaccine effectiveness (VE),

513 overall and stratified to age groups, virus subtypes and vaccine types.

**514** Horizontal bars indicated 95% confidence intervals (CI).

N	lo.of Case Patients/		
Subgroup	Total No.(%)		VE (95% CI)
Influenza A			
IIV3	97/963(10.07)		0.17 (-0.05-0.34)
IIV4	1283/8603(14.91)	•	0.40 (0.36-0.44)
LAIV3 (3 to 17 yr of age only)	100/517(19.34)	<b>_</b> _	0.25 (0.05-0.41)
Influenza B			
IIV3	20/886(2.26)		0.87 (0.79-0.91)
IIV4	1025/8345(12.28)	•	0.53 (0.50-0.57)
LAIV3 (3 to 17 yr of age only)	27/444(6.08)		0.79 (0.69-0.86)
	-0.5	0 0.5 1	
	Vac	cine effectiveness	

# 516 Figure 3. Adjusted VE against hospital-attended influenza A and B

517 infection, stratified to vaccine types.


511

	No.of Case Patients/		
Subgroup	Total No.(%)		VE (95% CI)
Overall			
Neither season	52484/140955(37.23)		Reference
Current and previous season	1198/4956(24.17)	+	0.45 (0.41-0.49)
Previous season only	1675/5188(32.29)	-	0.23 (0.18-0.27)
Current season only	1347/6192(21.75)	•	0.52 (0.49-0.55)
Influenza A			
Neither season	30096/118567(25.38)		Reference
Current and previous season	777/4535(17.13)	-	0.29 (0.23-0.35)
Previous season only	1098/4611(23.81)	-	0.12 (0.05-0.18)
Current season only	703/5548(12.67)	-	0.47 (0.42-0.51)
Influenza B			
Neither season	22442/110913(20.23)		Reference
Current and previous season	425/4183(10.16)	-	0.59 (0.55-0.63)
Previous season only	579/4092(14.15)		0.34 (0.28-0.40)
Current season only	647/5492(11.78)	-	0.56 (0.52-0.60)
	-0.5	0 0.5 1	_
		accine effectiveness	

## 

519 Figure 4. Adjusted VE against hospital-attended influenza A and B520 infection, stratified according to receipt of vaccines for the current season

(2023/24) and previous season (2022/23).



	No.of Case Patients/				
Subgroup	Total No.(%)		VE (95% CI)		
Overall	56704/157291(36.05)	-	0.48 (0.46-0.51)		
Vaccine type					
IIV3	116/982(11.81)		0.59 (0.50-0.66)		
IIV4	2303/9623(23.93)	-	0.47 (0.45-0.50)		
LAIV3 (3 to 17 yr of age only)	126/543(23.20)		0.53 (0.42-0.62)		
Age group					
0.5-2 years	1696/6659(25.47)		0.65 (0.54-0.72)		
3-9 years	13351/35408(37.71)	-	0.43 (0.39-0.47)		
10-17 years	10186/28718(35.47)		0.42 (0.36-0.48)		
18-59 years	29934/79270(37.76)		0.52 (0.43-0.58)		
60-69 years	1051/4403(23.87)	_ <b>_</b>	0.75 (0.59-0.85)		
70+ years	486/2833(17.15)	<b>-</b>	0.28 (0.07-0.44)		
Influenza subtype					
Influenza A	32674/133261(24.52)	-	0.38 (0.34-0.42)		
Influenza B	24093/124680(19.32)	-	0.57 (0.54-0.60)		
	-0.5 (	0.5 1			
	Vaccine effectiveness				

	No.of Case Patients/		
Subgroup	Total No.(%)		VE (95% CI)
Influenza A			
IIV3	97/963(10.07)		0.17 (-0.05-0.34)
IIV4	1283/8603(14.91)	+	0.40 (0.36-0.44)
LAIV3 (3 to 17 yr of age only)	100/517(19.34)	<b>-</b>	0.25 (0.05-0.41)
Influenza B			
IIV3	20/886(2.26)		0.87 (0.79-0.91)
IIV4	1025/8345(12.28)	+	0.53 (0.50-0.57)
LAIV3 (3 to 17 yr of age only)	27/444(6.08)	_ <b>_</b>	0.79 (0.69-0.86)
	-0.5	0 0.5 1	_
	Vacci	ne effectiveness	

	No.of Case Patients/					
Subgroup	Total No.(%)					VE (95% CI)
Overall						
Neither season	52484/140955(37.23)					Reference
Current and previous season	1198/4956(24.17)			•		0.45 (0.41-0.49)
Previous season only	1675/5188(32.29)		-			0.23 (0.18-0.27)
Current season only	1347/6192(21.75)			•		0.52 (0.49-0.55)
Influenza A						
Neither season	30096/118567(25.38)					Reference
Current and previous season	777/4535(17.13)					0.29 (0.23-0.35)
Previous season only	1098/4611(23.81)					0.12 (0.05-0.18)
Current season only	703/5548(12.67)			•		0.47 (0.42-0.51)
Influenza B						
Neither season	22442/110913(20.23)		   			Reference
Current and previous season	425/4183(10.16)			•		0.59 (0.55-0.63)
Previous season only	579/4092(14.15)		-			0.34 (0.28-0.40)
Current season only	647/5492(11.78)			+		0.56 (0.52-0.60)
	-0	0.5 (	0	0.5	1	_
		Vaccin	ne effe	ctiven	ess	